结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5% [1] ，但与其预后密切相关，并已成为 ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面 本文仅供医疗卫生等专业人士参考审批码：TML0038594，有效期为 2025-01-21 至 2026-01-20，资料过期，视同作废内容策划：方程项目审核：于轩题图来源：图虫创意参考文献：[1]Fan Y, Zhou JY, Zhao Y, et al. Efficacy, safety, and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

HER2-negative metastatic breast cancer, with promising results, especially when combined with abemaciclib, showing progression-free survival regardless of ESR1 mutation status. Dr Armaghani ...